NewAmsterdam Pharma Co N.V Income Statement (2022-2025) | NAMS

Income Statement Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.01B0.00B0.00B0.00B0.00B0.00B0.03B0.01B0.00B0.02B0.00B
Operating items
Research & Development -31.21B0.04B0.03B0.04B0.04B0.04B0.04B0.04B0.03B0.04B0.03B0.03B
Wages, Salaries and Other -1.91B
Selling, General & Administrative 0.01B0.01B0.01B0.01B0.01B0.02B0.02B0.02B0.03B0.03B0.02B
Other Operating Expenses -0.00B
Operating Expenses -31.21B0.05B0.04B0.05B0.05B0.06B0.05B0.05B0.06B0.07B0.05B0.06B
Operating Income -0.04B-0.04B-0.05B-0.05B-0.06B-0.05B-0.03B-0.04B-0.07B-0.04B-0.06B
EBIT -0.04B-0.04B-0.05B-0.05B-0.06B-0.05B-0.03B-0.04B-0.07B-0.04B-0.06B
Non-operating items
Interest & Investment Income 0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.01B0.01B0.01B
Other Non Operating Income 0.00B-0.00B-0.00B0.01B0.03B-0.01B0.00B0.02B-0.01B0.01B0.02B
Net income details
EBT -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Tax Provisions -0.00B
Profit After Tax -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Income from Continuing Operations -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Consolidated Net Income -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Income towards Parent Company -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Net Income towards Common Stockholders -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Additional items
EPS (Basic) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.95-0.34-0.15-0.61
EPS (Weighted Average and Diluted) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.95-0.34-0.15-0.61
Shares Outstanding (Weighted Average) 0.08B0.08B0.08B0.10B0.10B0.09B0.09B0.09B0.09B0.11B0.11B0.11B
Shares Outstanding (Diluted Average) 0.04B0.09B
EBITDA -0.04B-0.04B-0.05B-0.05B-0.09B-0.04B-0.02B-0.09B-0.04B-0.02B-0.07B
Shares Outstanding 0.08B0.08B0.08B0.08B0.08B0.09B0.09B0.09B0.11B0.11B0.11B0.11B
Tax Rate 0.01